FDA approves Acella’s generic Vituz oral solution

ATLANTA — Acella Pharmaceuticals has received approval from the U.S. Food and Drug Administration for its generic hydrocodone bitartrate and chlorpheniramine maleate oral solution, 5 mg/4 mg per 5 mL, as a bioequivalent of Vituz Oral Solution. The combination medicine is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years and older.

"Acella continues to actualize new product launch opportunities that align with our strategic mission to provide optimal healthcare support for the medical community and their patient population," said Harold A. Deas Jr., CEO for Acella Pharmaceuticals.